AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16700140 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained OPC beyond an initial court order
Number of subjects: 0
Study 10100139 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifetal pregnancy reduction
Number of subjects: 0
Study 10100139 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8659771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol (150 mg)
Number of subjects: 0
Study 8659771 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (2 mg bolus + 0.2 mg/h continuous infusion)
Number of subjects: 0
Study 1517926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil
Number of subjects: 229
Study 1517926 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 229
Study 6824247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and fluoxymesterone
Number of subjects: 108
Study 6824247 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 108
Study 30389347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I) combined with the modern neuroscience approach
Number of subjects: 120
Study 30389347 — intervention group
Group type: COMPARATOR
Intervention: Modern neuroscience approach alone
Number of subjects: 120
Study 29171486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin treatment
Number of subjects: 80
Study 26595559 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinent heroin abusers (AHs)
Number of subjects: 0
Study 26595559 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 0
Study 23273292 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 1395
Study 23273292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study 21696814 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey formula (pHWF)
Number of subjects: 620
Study 21696814 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula
Number of subjects: 620
Study 21696814 — intervention group
Group type: COMPARATOR
Intervention: Conventional cow's milk formula
Number of subjects: 620
Study 19155895 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sedation (10 mg of oxycodone and 1 mg of lorazepam)
Number of subjects: 130
Study 19155895 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation (100 micrograms fentanyl and 2 mg midazolam)
Number of subjects: 130
Study 19155895 — intervention group
Group type: COMPARATOR
Intervention: Comparison of oral sedation to intravenous sedation
Number of subjects: 130
Study 19155895 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adverse effects
Number of subjects: 130
Study 16565627 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week moderate-intensity aerobic exercise intervention
Number of subjects: 41
Study 16565627 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 14556856 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin concentration
Number of subjects: 669
Study 10751205 — intervention group
Group type: EXPERIMENTAL
Intervention: Men who were lighter or shorter as babies
Number of subjects: 163
Study 10751205 — intervention group
Group type: COMPARATOR
Intervention: Overall glucose tolerance
Number of subjects: 163
Study 10751205 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 163
Study 8617132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg four times a day for three days
Number of subjects: 12
Study 8617132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1418064 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline lactulose (60 g/d for 30 days)
Number of subjects: 20
Study 1418064 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 6319087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral digoxin (0.25 mg/day)
Number of subjects: 12
Study 6319087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30930896 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S vaccination
Number of subjects: 0
Study 30930896 — intervention group
Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 0
Study 28590157 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused narrative intervention in addition to usual care
Number of subjects: 57
Study 28590157 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 57
Study 26988348 — intervention group
Group type: EXPERIMENTAL
Intervention: GDm‐health system and half the normal clinic visits
Number of subjects: 0
Study 26988348 — intervention group
Group type: COMPARATOR
Intervention: Normal clinic care
Number of subjects: 0
Study 26988348 — intervention group
Group type: EXPERIMENTAL
Intervention: GDm‐health system
Number of subjects: 0
Study 24766387 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led counselling programme (Healthy Skin Clinic)
Number of subjects: 306
Study 24766387 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study 22375947 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial counselling (5-8 sessions)
Number of subjects: 61
Study 22375947 — intervention group
Group type: COMPARATOR
Intervention: Routine medical treatment (treatment as usual)
Number of subjects: 61
Study 19540054 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment plans meeting dose-volume constraints (V30<=80%, V40<=65%, V50<=55%, V60<=40%, V65<=30%, V70<=15%, V75<=3%)
Number of subjects: 0
Study 19540054 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 17535971 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vaccinia virus Ankara (MVA)
Number of subjects: 0
Study 17535971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dryvax
Number of subjects: 0
Study 16123531 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention
Number of subjects: 64
Study 16123531 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard plus family intervention
Number of subjects: 64
Study 16123531 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 64
Study 12365829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod treatment
Number of subjects: 0
Study 10426891 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin/TAC cream (0.025% triamcinolone acetonide)
Number of subjects: 24
Study 10426891 — intervention group
Group type: COMPARATOR
Intervention: Doxepin cream (5% doxepin hydrochloride)
Number of subjects: 24
Study 7547092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium 120 mg day‐1
Number of subjects: 12
Study 7547092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2158440 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 95962 (20 micrograms/kg body weight, 2 injections, 10 min apart)
Number of subjects: 6
Study 2158440 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 6
Study 2158440 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 95962
Number of subjects: 6
Study 7363678 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflo II
Number of subjects: 79
Study 7363678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bartlett‐Edwards Incentive Spirometer
Number of subjects: 79
Study 7363678 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirocare
Number of subjects: 79
Study 31275980 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOT
Number of subjects: 41
Study 31275980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 27129589 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal lollipops (C-1)
Number of subjects: 108
Study 25858634 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief health talk on cervical cancer
Number of subjects: 419
Study 25858634 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health talk)
Number of subjects: 419
Study 25858634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 419
Study 25858634 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 419
Study 24211163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg orally once daily) plus docetaxel (75 mg/m² intravenously every 3 weeks, plus oral prednisone 5 mg twice daily)
Number of subjects: 1522
Study 24211163 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel (75 mg/m² intravenously every 3 weeks, plus oral prednisone 5 mg twice daily)
Number of subjects: 1522
Study 24211163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg orally once daily) plus docetaxel
Number of subjects: 1522
Study 24211163 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 1522
Study 21430254 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of L-essential amino acids (EAA)
Number of subjects: 8
Study 21430254 — intervention group
Group type: COMPARATOR
Intervention: rapamycin (mTORC1 inhibitor) prior to EAA ingestion
Number of subjects: 8
Study 19646931 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine withdrawal
Number of subjects: 160
Study 19646931 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate withdrawal in women
Number of subjects: 160
Study 19646931 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonwithdrawal)
Number of subjects: 160
Study 17287702 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelson technique (as modified by Harris)
Number of subjects: 35
Study 17287702 — intervention group
Group type: COMPARATOR
Intervention: Langer technique
Number of subjects: 35
Study 15522364 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of blood and any associated CNV
Number of subjects: 336
Study 15522364 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 336
Study 16052904 — intervention group
Group type: EXPERIMENTAL
Intervention: DM+SE
Number of subjects: 249
Study 16052904 — intervention group
Group type: EXPERIMENTAL
Intervention: DM+TC
Number of subjects: 249
Study 16052904 — intervention group
Group type: EXPERIMENTAL
Intervention: DM+SE+TC
Number of subjects: 249
Study 16052904 — intervention group
Group type: COMPARATOR
Intervention: DM
Number of subjects: 249
Study 9213204 — intervention group
Group type: EXPERIMENTAL
Intervention: Saterinone
Number of subjects: 36
Study 9213204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8353700 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental home‐based psychiatric service
Number of subjects: 172
Study 8353700 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 172
Study 3305036 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 1004
Study 3305036 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 1004
Study 3305036 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 1004
Study 31838589 — intervention group
Group type: EXPERIMENTAL
Intervention: PATCH (motivational enhancement intervention)
Number of subjects: 34
Study 31838589 — intervention group
Group type: COMPARATOR
Intervention: Stress reduction skills control intervention
Number of subjects: 34
Study 29389484 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week spiritual counseling intervention
Number of subjects: 42
Study 29389484 — intervention group
Group type: COMPARATOR
Intervention: Routine education/care (control)
Number of subjects: 42
Study 25990354 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 172
Study 25990354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 172
Study 25990354 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 172
Study 25990354 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Number of subjects: 172
Study 24783925 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpi suppository
Number of subjects: 120
Study 24783925 — intervention group
Group type: COMPARATOR
Intervention: mesalazine
Number of subjects: 120
Study 23240940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal reduced glutathione (in)GSH
Number of subjects: 70
Study 20515959 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented formula
Number of subjects: 107
Study 20515959 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented formula
Number of subjects: 107
Study 18650154 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2
Number of subjects: 76
Study 18650154 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2
Number of subjects: 76
Study 18650154 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin/Cyclophosphamide (AC)
Number of subjects: 76
Study 17092412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin plus thymosin-alpha1 on the base of regular therapy for 1 week
Number of subjects: 70
Study 12872390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined medicine (CAL and western medicine)
Number of subjects: 110
Study 12872390 — intervention group
Group type: COMPARATOR
Intervention: CAL (composite agastache lotion)
Number of subjects: 110
Study 12872390 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 110
Study 10693835 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype gloves (two pairs with different levels of protection)
Number of subjects: 0
Study 10693835 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype II (laminar glove)
Number of subjects: 0
Study 10693835 — intervention group
Group type: COMPARATOR
Intervention: Double glove
Number of subjects: 0
Study 8673643 — intervention group
Group type: EXPERIMENTAL
Intervention: List-making
Number of subjects: 0
Study 8673643 — intervention group
Group type: COMPARATOR
Intervention: Non-list-making
Number of subjects: 0
Study 8673643 — intervention group
Group type: EXPERIMENTAL
Intervention: List-making (organized)
Number of subjects: 0
Study 8673643 — intervention group
Group type: EXPERIMENTAL
Intervention: List-making (non-organized)
Number of subjects: 0
Study 1762283 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (20 patients), daily dose 60‐120 mg, mean 80 mg
Number of subjects: 40
Study 1762283 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (20 patients), daily dose 120‐180 mg, mean 140 mg
Number of subjects: 40
Study 7050868 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (2.5 mg/kg q6h)
Number of subjects: 100
Study 7050868 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin (1 mg/kg q6h)
Number of subjects: 100
Study 7050868 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 7050868 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sensitivity patterns
Number of subjects: 100
Study 7050868 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of neonatal sepsis
Number of subjects: 100
Study 4026058 — intervention group
Group type: COMPARATOR
Intervention: HFCWO at 5 Hz with 20 ml tidal volume (Series B)
Number of subjects: 7
Study 4026058 — intervention group
Group type: COMPARATOR
Intervention: HFCWO at 5 Hz with 40 ml tidal volume (Series C)
Number of subjects: 7
Study 4026058 — intervention group
Group type: COMPARATOR
Intervention: Control condition (Series A)
Number of subjects: 7
Study 31197507 — intervention group
Group type: EXPERIMENTAL
Intervention: Juçara freeze-dried pulp (5 g)
Number of subjects: 27
Study 31197507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 g)
Number of subjects: 27
Study 28447466 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy and education intervention (personal contacts and theory-based training and materials)
Number of subjects: 98
Study 27484783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 68
Study 27484783 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 68
Study 27484783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Remifentanil
Number of subjects: 68
Study 24314823 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson-stress myocardial CT perfusion (CTP)
Number of subjects: 0
Study 24314823 — intervention group
Group type: COMPARATOR
Intervention: Single-photon emission CT (SPECT)
Number of subjects: 0
Study 21305260 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative hypothesis testing (IHT) training for 4 weeks
Number of subjects: 71
Study 21305260 — intervention group
Group type: COMPARATOR
Intervention: Medical teaching as usual
Number of subjects: 71
Study 20465558 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolisation (UAE)
Number of subjects: 96
Study 20465558 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 96
Study 19026912 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making program
Number of subjects: 0
Study 15974350 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise group
Number of subjects: 45
Study 15974350 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise group
Number of subjects: 45
Study 15974350 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 12209020 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) program for 9 weeks
Number of subjects: 20
Study 10609975 — intervention group
Group type: EXPERIMENTAL
Intervention: MTT with contingency contracts using monetary reinforcers targeting abstinence from illicit drug and alcohol use
Number of subjects: 102
Study 10609975 — intervention group
Group type: COMPARATOR
Intervention: MTT without contingency contracts targeting abstinence
Number of subjects: 102
Study 7489456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (120-180 micrograms.kg-1 min-1)
Number of subjects: 39
Study 7489456 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.8-1.6%)
Number of subjects: 39
Study 1777375 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 8
Study 1777375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31552704 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min aerobic exercise
Number of subjects: 18
Study 31552704 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min aerobic exercise
Number of subjects: 18
Study 31552704 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-min aerobic exercise
Number of subjects: 18
Study 31501887 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/day)
Number of subjects: 340
Study 31501887 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (40 mg/m2/week)
Number of subjects: 340
Study 31501887 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 340
Study 31501887 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 340
Study 29429823 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal palpation
Number of subjects: 132
Study 29429823 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal palpation with posterior pelvic tilt
Number of subjects: 132
Study 29429823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal electrical stimulation
Number of subjects: 132
Study 29429823 — intervention group
Group type: COMPARATOR
Intervention: Control group (verbal instructions)
Number of subjects: 132
Study 27029489 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach-based interventions focused on breastfeeding, weight loss, healthy eating, and increased physical activity, predominantly delivered by telephone.
Number of subjects: 740
Study 27029489 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 740
Study 24451954 — intervention group
Group type: EXPERIMENTAL
Intervention: SVV group (using Pulse Indication Continuous Cardiac Output monitoring of SVV, responsiveness defined as SVV ≥12%)
Number of subjects: 58
Study 24451954 — intervention group
Group type: COMPARATOR
Intervention: PLR-ΔSV group (using ΔSV before and after PLR as the indicator, responsiveness defined as ΔSV ≥15%)
Number of subjects: 58
Study 24451954 — intervention group
Group type: EXPERIMENTAL
Intervention: SVV group
Number of subjects: 58
Study 24451954 — intervention group
Group type: COMPARATOR
Intervention: PLR-ΔSV group
Number of subjects: 58
Study 24451954 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 23019074 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 20397495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast gold post‐and‐core group (GG)
Number of subjects: 50
Study 20397495 — intervention group
Group type: EXPERIMENTAL
Intervention: Heraplat post/cast gold core group (HG)
Number of subjects: 50
Study 20397495 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium post/composite core (TC)
Number of subjects: 50
Study 20397495 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium post/cast gold core (TG)
Number of subjects: 50
Study 20397495 — intervention group
Group type: COMPARATOR
Intervention: Endodontically treated teeth without posts (ETT, control)
Number of subjects: 50
Study 17011666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous progesterone
Number of subjects: 100
Study 17011666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16272751 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (low dose: 0.03 mg/kg/min for 1 min loading, then 0.01 mg/kg/min for 10 min continuous)
Number of subjects: 16
Study 16272751 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (medium dose: 0.06 mg/kg/min for 1 min loading, then 0.02 mg/kg/min for 10 min continuous)
Number of subjects: 16
Study 16272751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11579113 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC (fluorouracil, epirubicin, and cyclophosphamide) chemotherapy, six cycles
Number of subjects: 248
Study 11579113 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant therapy)
Number of subjects: 248
Study 11301565 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (5 mg)
Number of subjects: 16